Effects of Tirofiban combined with dual antiplatelet therapy in patients with progressive cerebral infarction
Objective:To observe effects of Tirofiban combined with dual antiplatelet therapy in patients with progressive cerebral infarction.Methods:A prospective study was conducted on 80 patients with progressive cerebral infarction admitted to the hospital from May 2022 to May 2023.They were divided into control group and observation group by using the random number table method,40 cases in each group.The control group was treated with dual antiplatelet therapy,while the observation group was treated with Tirofiban on the basis of that of the control group.The clinical efficacy,the neurological deficit score[National Institutes of Health stroke scale(NIHSS)]score,the activities of daily living[Barthel Index(BI)]score,the inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP)]levels,the platelet function index[platelet granule membrane protein 140(GMP-140),thromboxane B2(TXB2)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.50%(37/40),which was higher than 75.00%(30/40)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS scores of the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;the BI scores of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of GMP-140 and TXB2 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tirofiban combined with dual antiplatelet therapy in the patients with progressive cerebral infarction can improve the total effective rate of treatment and the BI scores and reduce the NIHSS scores,the inflammatory factor level and the platelet function index levels.Moreover,it is superior to single dual antiplatelet therapy.
NETL
NSTL
万方数据
